199 related articles for article (PubMed ID: 15555579)
21. Responses of normal and sickle cell hemoglobin to S-nitroscysteine: implications for therapeutic applications of NO in treatment of sickle cell disease.
Bonaventura C; Godette G; Ferruzzi G; Tesh S; Stevens RD; Henkens R
Biophys Chem; 2002 Jul; 98(1-2):165-81. PubMed ID: 12128197
[TBL] [Abstract][Full Text] [Related]
22. High oxygen environment during pregnancy rescues sickle cell anemia mice from prenatal death.
Ye L; Chang JC; Lu R; Kan YW
Blood Cells Mol Dis; 2008; 41(1):67-72. PubMed ID: 18207438
[TBL] [Abstract][Full Text] [Related]
23. Antisickling effects of an endogenous human alpha-like globin.
He Z; Russell JE
Nat Med; 2004 Apr; 10(4):365-7. PubMed ID: 15034572
[TBL] [Abstract][Full Text] [Related]
24. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
Pagare PP; Ghatge MS; Musayev FN; Deshpande TM; Chen Q; Braxton C; Kim S; Venitz J; Zhang Y; Abdulmalik O; Safo MK
Bioorg Med Chem; 2018 May; 26(9):2530-2538. PubMed ID: 29655608
[TBL] [Abstract][Full Text] [Related]
25. A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin.
Levasseur DN; Ryan TM; Reilly MP; McCune SL; Asakura T; Townes TM
J Biol Chem; 2004 Jun; 279(26):27518-24. PubMed ID: 15084588
[TBL] [Abstract][Full Text] [Related]
26. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
27. Roles of alpha 114 and beta 87 amino acid residues in the polymerization of hemoglobin S: implications for gene therapy.
Ho C; Willis BF; Shen TJ; Dazhen NT; Sun DP; Tam MF; Suzuka SM; Fabry ME; Nagel RL
J Mol Biol; 1996 Nov; 263(3):475-85. PubMed ID: 8918602
[TBL] [Abstract][Full Text] [Related]
28. Effects of substitutions of lysine and aspartic acid for asparagine at beta 108 and of tryptophan for valine at alpha 96 on the structural and functional properties of human normal adult hemoglobin: roles of alpha 1 beta 1 and alpha 1 beta 2 subunit interfaces in the cooperative oxygenation process.
Tsai CH; Shen TJ; Ho NT; Ho C
Biochemistry; 1999 Jul; 38(27):8751-61. PubMed ID: 10393550
[TBL] [Abstract][Full Text] [Related]
29. Nitric oxide transport on sickle cell hemoglobin: where does it bind?
Gladwin MT; Ognibene FP; Shelhamer JH; Pease-Fye ME; Noguchi CT; Rodgers GP; Schechter AN
Free Radic Res; 2001 Aug; 35(2):175-80. PubMed ID: 11697198
[TBL] [Abstract][Full Text] [Related]
30. Anti-beta s-ribozyme reduces beta s mRNA levels in transgenic mice: potential application to the gene therapy of sickle cell anemia.
Alami R; Gilman JG; Feng YQ; Marmorato A; Rochlin I; Suzuka SM; Fabry ME; Nagel RL; Bouhassira EE
Blood Cells Mol Dis; 1999 Apr; 25(2):110-9. PubMed ID: 10389593
[TBL] [Abstract][Full Text] [Related]
31. Nitric oxide-mediated heme oxidation and selective beta-globin nitrosation of hemoglobin from normal and sickle erythrocytes.
Hrinczenko BW; Schechter AN; Wojtkowski TL; Pannell LK; Cashon RE; Alayash AI
Biochem Biophys Res Commun; 2000 Sep; 275(3):962-7. PubMed ID: 10973828
[TBL] [Abstract][Full Text] [Related]
32. Strategy for identification by mass spectrometry of a new human hemoglobin variant with two mutations in Cis in the beta-globin chain: Hb S-Clichy [beta6(A3)Glu-->Val; beta8(A5)Lys-->Thr].
Zanella-Cleon I; Préhu C; Joly P; Riou J; Becchi M; Wajcman H; Francina A
Hemoglobin; 2009; 33(3):177-87. PubMed ID: 19657831
[TBL] [Abstract][Full Text] [Related]
33. Modification of hemoglobin H disease by sickle trait.
Matthay KK; Mentzer WC; Dozy AM; Kan YW; Bainton DF
J Clin Invest; 1979 Oct; 64(4):1024-32. PubMed ID: 479366
[TBL] [Abstract][Full Text] [Related]
34. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity.
Fabry ME; Sengupta A; Suzuka SM; Costantini F; Rubin EM; Hofrichter J; Christoph G; Manci E; Culberson D; Factor SM; Nagel RL
Blood; 1995 Sep; 86(6):2419-28. PubMed ID: 7662990
[TBL] [Abstract][Full Text] [Related]
35. Enhanced inhibition of polymerization of sickle cell hemoglobin in the presence of recombinant mutants of human fetal hemoglobin with substitutions at position 43 in the gamma-chain.
Tam MF; Chen J; Tam TC; Tsai CH; Shen TJ; Simplaceanu V; Feinstein TN; Barrick D; Ho C
Biochemistry; 2005 Sep; 44(36):12188-95. PubMed ID: 16142917
[TBL] [Abstract][Full Text] [Related]
36. Hb S-São Paulo: a new sickling hemoglobin with stable polymers and decreased oxygen affinity.
Jorge SE; Petruk AA; Kimura EM; Oliveira DM; Caire L; Suemasu CN; Silveira PA; Albuquerque DM; Costa FF; Skaf MS; Martínez L; Sonati Mde F
Arch Biochem Biophys; 2012 Mar; 519(1):23-31. PubMed ID: 22244832
[TBL] [Abstract][Full Text] [Related]
37. Chimeric beta-EF3-alpha hemoglobin (Psi): energetics of subunit interaction and ligand binding.
Kiger L; Dumoulin A; Edelstein SJ; Abraham DJ; Promé D; Poyart C; Marden MC; Pagnier J
Biochemistry; 1998 May; 37(20):7328-39. PubMed ID: 9585547
[TBL] [Abstract][Full Text] [Related]
38. Towards a mouse model for sickle cell disease: HB SAD.
Trudel M; Garel MC; Saadane N; Rouyer-Fessard P; Vidaud D; Costantini F; Beuzard Y
Nouv Rev Fr Hematol (1978); 1990; 32(6):407-8. PubMed ID: 2101873
[TBL] [Abstract][Full Text] [Related]
39. Human embryonic, fetal, and adult hemoglobins have different subunit interface strengths. Correlation with lifespan in the red cell.
Manning LR; Russell JE; Padovan JC; Chait BT; Popowicz A; Manning RS; Manning JM
Protein Sci; 2007 Aug; 16(8):1641-58. PubMed ID: 17656582
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for the antipolymer activity of Hb ζ
Safo MK; Ko TP; Schreiter ER; Russell JE
J Mol Struct; 2015 Nov; 1099():99-107. PubMed ID: 26207073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
